fraxiparine 5 700 iu (anti xa)/0,6 ml
viatris healthcare limited, Írsko - nadroparín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
fraxiparine 2 850 iu (anti xa)/0,3 ml
viatris healthcare limited, Írsko - nadroparín - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
gopten 2 mg
viatris healthcare limited, Írsko - trandolapril - 58 - hypotensiva
ciclosporin viatris 25 mg
viatris limited, Írsko - cyklosporín - 59 - immunopraeparata
ciclosporin viatris 50 mg
viatris limited, Írsko - cyklosporín - 59 - immunopraeparata
ciclosporin viatris 100 mg
viatris limited, Írsko - cyklosporín - 59 - immunopraeparata
metformin viatris 1000 mg
viatris limited, Írsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin viatris 750 mg
viatris limited, Írsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
metformin viatris 500 mg
viatris limited, Írsko - metformín - 18 - antidiabetica (vrÁtane inzulÍnu)
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrel besilát - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidlá - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segment elevation akútnom infarkte myokardu v kombinácii s asa u medicínsky liečiť pacientov nárok na thrombolytic therapy. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. Ďalšie informácie nájdete v časti 5.